What is Plexium?
Plexium is a specialized biotechnology firm focused on the identification of E3 ligase modulating small molecules. The company's core innovation, the DELPhe platform, utilizes DNA-Encoded Library phenotypic screening to miniaturize cell-based assays. By employing droplet and microwell confinement, Plexium achieves high-throughput, high-content readouts at a fraction of the cost of traditional methods. This technological advantage allows the company to rapidly identify novel therapeutic candidates, positioning it as a leader in the next generation of precision medicine and targeted protein degradation.
How much funding has Plexium raised?
Plexium has raised a total of $225.1M across 4 funding rounds:
Series A
$28M
Other Financing Round
$35M
Other Financing Round
$102M
Private Equity
$60.1M
Series A (2019): $28M with participation from M Ventures, DCVC Bio, The Column Group, Neotribe Ventures, and CRV
Other Financing Round (2021): $35M led by PIVOTAL BIOVENTURE PARTNERS LLC, DCVC Bio, Lux Capital, and The Column Group
Other Financing Round (2022): $102M supported by Surveyor Capital, Softbank Vision Fund 2, RA Capital Management, Pappas Capital, L.P., BVF Partners, and TCG X
Private Equity (2025): $60.1M, investors not publicly disclosed
Key Investors in Plexium
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that nurtures platforms from inception to exit.
DCVC Bio
DCVC Bio is a deep tech venture capital firm that leverages artificial intelligence to unlock potential in biotechnology, supporting ambitious founders tackling the world's most challenging problems.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, utilizing its internal think tank to support scientific breakthroughs.
What's next for Plexium?
With the recent infusion of $60.1M, Plexium is poised to scale its operational capacity and advance its lead programs into clinical development. The strategic focus will likely center on expanding the utility of the DELPhe platform to explore new biological targets, thereby strengthening its competitive moat in the life sciences market. As the company matures, the emphasis will shift toward establishing high-value partnerships and accelerating the transition of its pipeline from the laboratory to clinical trials, ultimately aiming to deliver transformative treatments for patients suffering from cancer and neurodegenerative conditions.
See full Plexium company page
